Evidence map›Paper›PMID 37025999›Full record

ReviewFrontiers in immunology2023

Autoimmune encephalitis with mGluR5 antibodies: A case series from China and review of the literature.

Kundian Guo, Xu Liu, Xue Gong, Aiqing Li, Yue Liu, Xingjie Li, Dong Zhou, Zhen Hong

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Mapping Cognitive Oncology: A Decade of Trends and Research Fronts.Medical sciences (Basel, Switzerland) · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Decoding Dystonia in Autoimmune Disorders: A Scoping Review.Tremor and other hyperkinetic movements (New York, N.Y.) · 2024
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kundian GuoDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xu LiuDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xue GongDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Aiqing LiDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yue LiuDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xingjie LiDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Dong ZhouDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhen HongDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
West China Hospital of Sichuan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Only 15 patients of autoimmune encephalitis with metabotropic glutamate receptor 5 (mGluR5) antibodies have been reported worldwide since 2011, mostly from western countries. Patients with different genetic backgrounds are necessary to further clarify the clinical phenotype and prognosis of this rare disease. Objective: We initially describe a case series from China to confirm the previous findings, expand the clinical phenotype, and identify the prognostic factors of autoimmune encephalitis with mGluR5 antibodies. Methods: Observational data with follow-up were prospectively collected from autoimmune encephalitis patients with mGluR5 antibodies. Clinical information and outcomes on current and previously reported cases were combined and analyzed. Results: We identified five patients (median age 35 years); two were female. The main clinical manifestations were behavioral/personality changes (five of five, 100%) and cognitive disorders (four of five, 80%), accompanied with other neurologic symptoms. Hypoventilation occurred in two (40%) patients, which was life-threatening. One patient had meningoencephalitis, suggesting a new phenotype in anti-mGluR5 encephalitis. All patients received immunotherapy. At the last follow-up (median 18 months), two (40%) patients showed complete recovery, two (40%) patients showed partial recovery, and one (20%) patient died. One (20%) patient had multiple relapses. Together with the 15 previously reported cases, associated tumors occurred in seven of 12 (58%) Western patients vs. one of eight (13%) Chinese patients. Modified Rankin Scale (mRS) scores at the last follow-up (median 31 months) were available in 16 patients. Patients with bad outcomes (mRS > 2, n = 4) were more likely to have hypoventilation at onset and higher mRS scores at peak of the disease. Conclusions: In patients with different genetic background, as Chinese, the clinical phenotype of anti-mGluR5 encephalitis is similar. Fewer paraneoplastic cases were observed in Chinese patients. Most patients showed good responses to immunotherapy and cancer treatment. The clinical outcomes were favorable in most patients.

Indexed as

Autoimmune Diseases of the Nervous SystemEncephalitisAdultAutoantibodiesFemaleHashimoto DiseaseHumansHypoventilationMaleObservational Studies as TopicReceptor, Metabotropic Glutamate 5AutoantibodiesReceptor, Metabotropic Glutamate 5autoimmune encephalitisChinametabotropic glutamate receptor 5Ophelia syndromeoutcome

Identifiers

PMID37025999
PMCPMC10070949
OpenAlexW4328118214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.